Please assess the completion status of the following clinical trial:

Trial Title: Botox vs. Baclofen for Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient, male or female subjects of any race, and at least 18 years of age. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 50mlU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study;~* Minimal 4-month history stable neurological disorder resulting focal upper limb muscle spasticity (wrist and/or elbow)~* Disability Assessment Scale (DAS) ≥ 2 for the principal therapeutic intervention target as chosen by Investigator and Subject (i.e., hygiene, dressing, pain and cosmesis).~* Subjects who are able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms.~Exclusion Criteria:~* Female subjects who are pregnant (positive urine pregnancy test) or who have an infant they are breast-feeding or who are of childbearing potential and are not practicing a reliable method of birth control.~* Severe contracture at the wrist or a history of tendon transfer in the study limb.~* Cast of study limb within four weeks of Visit 1.~* Profound atrophy of the muscles in the target area(s) of injection.~* Progressive neurological disorder (e.g., multiple sclerosis).~* Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.~* Orthostatic hypotension or current use of alpha-2 adrenergic agonists (e.g. clonidine).~* Current anticoagulant therapy and INR \> 3.5~* Significantly impaired renal and/or hepatic function, in the opinion of the Investigator.~* Failure to meet prohibited concomitant medication criteria (Supplement I)~* Subjects planning inpatient surgery during the study.~* Any uncontrolled systemic disease.~* Allergy or sensitivity to any component of the study medication.~* Recent alcohol or drug abuse.~* History of poor cooperation, non-compliance with medical treatment, or unreliability.~* Subjects currently participating in an investigational drug study or who have participated in an investigational drug study within 30 days of the Baseline Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.

Based on this trial design, predict the completion outcome and termination type (if applicable).